Response to: Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response" by Bonelli et al
- PMID: 34340982
- DOI: 10.1136/annrheumdis-2021-220997
Response to: Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response" by Bonelli et al
Keywords: B-lymphocytes; COVID-19; rituximab.
Conflict of interest statement
Competing interests: None declared.
Comment on
-
Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response" by Bonelli et al.Ann Rheum Dis. 2021 Oct;80(10):e164. doi: 10.1136/annrheumdis-2021-220972. Epub 2021 Aug 2. Ann Rheum Dis. 2021. PMID: 34340978 No abstract available.
-
Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response"by Bonelli et al.Ann Rheum Dis. 2021 Oct;80(10):e166. doi: 10.1136/annrheumdis-2021-220829. Epub 2021 Aug 2. Ann Rheum Dis. 2021. PMID: 34340979 No abstract available.
-
Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response" by Bonelli et al.Ann Rheum Dis. 2021 Oct;80(10):e165. doi: 10.1136/annrheumdis-2021-220957. Epub 2021 Aug 2. Ann Rheum Dis. 2021. PMID: 34340981 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
